Earnings are out
Anavex Life Sciences
Develops oral investigational therapies for neurodegenerative and neurodevelopmental diseases.
$2.99
After-hours close+0.00 (+0.14%)
At close$2.99(−4.63%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 40.69%37.71M sharesInsiders 1.68%1.55M sharesOther 57.63%53.41M shares
Shares outstanding 92.67M · Float 89.78M · 96.9% free float
Institutions13F, as of Jun 30, 2026
187 holders · 37.71M shares · 25 new positions · 88 increased · 58 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.06M | 8.69% | +446.0K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 4.05M | 4.38% | +190.6K | Aug 13, 2026 |
| Two Sigma Investments, LP | 3.05M | 3.29% | −201.4K | Aug 14, 2026 |
| Geode Capital Management, LLC | 2.41M | 2.60% | +219.2K | Aug 12, 2026 |
| State Street Corp | 1.92M | 2.07% | −2.59M | Aug 7, 2026 |
| Federated Hermes, Inc. | 1.07M | 1.16% | +539.6K | Aug 12, 2026 |
| AQR Capital Management LLC | 963.0K | 1.04% | +206.2K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 948.6K | 1.02% | +165.5K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Vanguard Capital Management | 5.03% | 4.66M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Christopher U. Missling | director, officer: President and CEO | 1.51M | 1.63% | Sep 12, 2025 |
| Steffen Thomas | director | 43.7K | 0.05% | Jun 9, 2025 |
5 people have not refiled in the last 18 months (1.47M shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.